Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer

Canadian Journal of Surgery

Volumn 49, Issue 4, 2006, Pages 241-244

  Kiliç, Mehmet ^a   Göçmen, Erdal ^a   Tez, Mesut ^a,b   Ertan, Tamer ^a   Keskek, Mehmet ^a   Koç, Mahmut ^a  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HUMAN; LAPAROTOMY; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PHYSICAL EXAMINATION; PREOPERATIVE PERIOD; RADIODIAGNOSIS; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; CA-19-9 ANTIGEN; FEMALE; HUMANS; LAPAROSCOPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PREDICTIVE VALUE OF TESTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 33748941924     PISSN: 0008428X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Vogt DP. Pancreatic cancer: a current overview. Curr Surg 2000;57:214-20.
2. Magee CJ, Ghaneh P, Neoptolemos JP. Surgical and medical therapy for pancreatic carcinoma. Best Pract Res Clin Gastroenterol 2002;16:435-55.
3. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer. Arch Surg 2003;138:951-5.
4. Pisters PW, Lee JE, Vauthney JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001;88:325-37.
5. Kau SY, Shyr YM, Su CH, et al. Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers. J Am Coll Surg 1999;188:415-20.
6. Osswald BR, Klee FE, Wysocki S. The reliability of highly elevated CA 19-9 levels. Dis Markers 1993;11:275-8.
7. Lind PA, Marks LB, Hollis D, et al. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys 2002;54:340-7.
8. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
9. Bottger T, Engelman R, Seifert JK, et al. Preoperative diagnostics in pancreatic carcinoma: Would less be better? Langenbecks Arch Surg 1998;383:243-8.
10. Lundin J, Roberts PJ, Kuusela P, et al. The prognostic value of preoperative serum levels of CA 19-9 and CEA in patients with pancreatic cancer. Br J Cancer 1994;69:515-9.
11. Haglund C, Lundin J, Kuusela P, et al. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 1994;70:487-92.
12. Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA 19-9. Pancreas 1994;9:731-4.
13. Mann DV, Edwards RS, Ho Siglazer G. Elevated tumour marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000;26:474-9.